Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.63 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.63 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761319 | 1.00 | PARP1 (0.63) | PARP1PARP10PARP15MEN1KMT2A | |
| SCHEMBL5605819 | 0.90 | CSF1R (0.60) | PARP1PARP10PARP15MEN1KMT2A | |
| SCHEMBL474709 | 0.86 | KMT2A (0.70) | MEN1KMT2AALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL1436168 | 0.86 | ALDH1A1 (0.59) | MEN1KMT2AALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL7875123 | 0.86 | PARP1 (0.60) | PARP1PARP10PARP15MEN1KMT2A | |
| SCHEMBL2850002 | 0.85 | MEN1 (0.67) | PARP1PARP10PARP15MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3576551 | 0.84 | ALDH1A1 (0.57) | MEN1KMT2AALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL4893340 | 0.83 | PARP1 (0.66) | PARP1PARP10PARP15MEN1KMT2A | |
| SCHEMBL31022695 | 0.83 | MEN1 (0.62) | MEN1KMT2AALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL5425792 | 0.83 | MEN1 (0.65) | PARP1PARP10PARP15MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| CN-101795665-A | Method for regulating hair growth | PROCTER & GAMBLE | 2010-08-04 | — | — | CN | claimed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| EP-2164457-A2 | METHOD OF REGULATING HAIR GROWTH | The Procter and Gamble Company (US) | 2010-03-24 | — | — | EP | claimed |
| US-20100016782-A1 | Method of Regulating Hair Growth | PROCTER & GAMBLE COMPANY, THE | 2010-01-21 | — | — | US | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| WO-2009010921-A2 | METHOD OF REGULATING HAIR GROWTH | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-22 | — | — | WO | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| US-5874444-A | CONTROLLING CELL AGING | GERON CORPORATION (US) | 1999-02-23 | — | — | US | claimed |
| WO-1998027975-A1 | POLY(ADP-RIBOSE) POLYMERASE INHIBITORS TO TREAT DISEASES ASSOCIATED WITH CELLULAR SENESCENCE | GERON CORPORATION (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0775110-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-05-28 | — | — | EP | claimed |
| WO-1996004242-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-15 | — | — | WO | claimed |
| US-20240180891-A1 | SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-10-03 | — | — | US | disclosed |
| WO-2022140279-A1 | SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220031641-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION | PHARMATROPHIX, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20200239512-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2020-07-30 | — | — | US | disclosed |
| WO-2020154434-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION | PHARMATROPHIX, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2526942-B1 | Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2017-08-09 | — | — | EP | disclosed |
| US-9604907-B2 | Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-03-28 | — | — | US | disclosed |
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| EP-2172198-B1 | p27 PROTEIN INDUCER | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2484680-B1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2308874-B1 | Bridged monobactams useful as beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-8278465-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-02 | — | — | US | disclosed |
| EP-1982982-B1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2484680-A1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | Basilea Pharmaceutica AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2440034-A1 | HIGH OIL CONTENT PLANTS | Bayer BioScience N.V. (BE) | 2012-04-18 | — | — | EP | disclosed |
| US-20120084883-A1 | High Oil Content Plants | BAYER CROPSCIENCE N.V. (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-1965798-B1 | USEFUL MONOBACTAM ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-2308874-A1 | Useful beta-lactamase inhibitors | Basilea Pharmaceutica AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010142424-A1 | HIGH OIL CONTENT PLANTS | BAYER BIOSCIENCE N.V. (BE) | 2010-12-16 | — | — | WO | disclosed |
| CN-101795665-A | Method for regulating hair growth | PROCTER & GAMBLE | 2010-08-04 | — | — | CN | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2164457-A2 | METHOD OF REGULATING HAIR GROWTH | The Procter and Gamble Company (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100016782-A1 | Method of Regulating Hair Growth | PROCTER & GAMBLE COMPANY, THE | 2010-01-21 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2083014-A2 | Inhibitors of interleukin-1ß converting enzyme | Vertex Pharmceuticals Incorporated (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7507748-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2009010921-A2 | METHOD OF REGULATING HAIR GROWTH | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1971604-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| EP-1562933-B1 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-7101868-B2 | Substituted arylamine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-7102009-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1694357-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-6979741-B2 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1583744-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1478437-B1 | ACC INHIBITORS | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1562933-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | Amgen Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005058348-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| CN-1135436-C | Silver halide photosensitive material | ������������ʽ���� | 2004-01-21 | — | — | CN | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20020198135-A1 | Compositions for release of radiosensitizers, and methods of making and using the same | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2002-12-26 | — | — | US | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002030472-A2 | COMPOSITIONS FOR RELEASE OF RADIOSENSITIZERS, AND METHODS OF MAKING AND USING THE SAME | GUILFORD PHARMACEUTICALS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| US-6358975-B1 | ADMINISTERING 3,4-DIHYDRO-5-(4-(1-PIPERIDINYL)-BUTOX)-1 (2H)-ISOQUINOLINONE, A SELECTIVE INHIBITOR OF POLY(ADP-RIBOSE) POLYMERASE FOR PROPHYLAXIS OF NEURAL TISSUE DAMAGE RESULTING FROM ISCHEMIA AND REPERFUSION INJURY OR NEURODEGENERATIVE | JOHNS HOPKINS UNIVERSITY | 2002-03-19 | — | — | US | disclosed |
| WO-1999008680-A1 | METHOD OF USING SELECTIVE PARP INHIBITORS TO PREVENT OR TREAT NEUROTOXICITY | THE JOHNS HOPKINS UNIVERSITY (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5874444-A | CONTROLLING CELL AGING | GERON CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
| CN-1208473-A | Silver halide photographic light-sensitive material | KONISHIROKU PHOTO IND (JP) | 1999-02-17 | — | — | CN | disclosed |
| WO-1998027975-A1 | POLY(ADP-RIBOSE) POLYMERASE INHIBITORS TO TREAT DISEASES ASSOCIATED WITH CELLULAR SENESCENCE | GERON CORPORATION (US) | 1998-07-02 | — | — | WO | disclosed |
| US-5719151-A | PHTHALAZINEDIONE COMPOUND; POLYMERASE INHIBITOR | SHALL SYDNEY (GB) | 1998-02-17 | — | — | US | disclosed |
| US-5641613-A | SUPPORT BEARING LIGHT SENSITIVE SILVER HALIDE LAYER CONTAINING BICYCLIC AZOLE COUPLER, AZOPYRAZOLONE MASKING COUPLER, LOW IMPACT DEVELOPMENT INHIBITOR RELEASING COUPLER | EASTMAN KODAK COMPANY (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0775110-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5633282-A | ENZYME INHIBITORS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-05-27 | — | — | US | disclosed |
| US-5589483-A | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence | GERON CORPORATION (US) | 1996-12-31 | — | — | US | disclosed |
| EP-0531370-B1 | INHIBITION OF VIRAL INFECTION | BRITISH TECH GROUP (GB) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996004242-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0646842-A1 | Photographic element containing an azopyrazolone masking coupler exhibiting improved keeping | EASTMAN KODAK COMPANY (US) | 1995-04-05 | — | — | EP | disclosed |
| EP-0232101-B1 | Light-sensitive silver halide color photographic material | KONISHIROKU PHOTO IND (JP) | 1994-03-23 | — | — | EP | disclosed |
| EP-0531370-A1 | INHIBITION OF VIRAL INFECTION. | COLLINS MARY KATHARINE LEVINGE (GB) | 1993-03-17 | — | — | EP | disclosed |
| WO-1991018591-A1 | INHIBITION OF VIRAL INFECTION | COLLINS MARY KATHARINE LEVINGE (GB) | 1991-12-12 | — | — | WO | disclosed |
| US-5051342-A | Sharpness, whiteness | FUJI PHOTO FILM CO., LTD. (JP) | 1991-09-24 | — | — | US | disclosed |
| US-4914013-A | MAGENTA COUPLER HAVING SPECIFIC BALLAST GROUP | KONICA CORPORATION (JP) | 1990-04-03 | — | — | US | disclosed |
| US-4880726-A | TRANSMITTING LIGHT THROUGH A BAND STOP FILTER; REDUCED COLOR MIXING | FUJI PHOTO FILM CO., LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| EP-0334654-A2 | Silver halide light-sensitive color photographic material | KONICA CORPORATION (JP) | 1989-09-27 | — | — | EP | disclosed |
| US-4818672-A | CYAN COUPLER OF SUBSTITUTED DIPHENYL IMIDAZOLE | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1989-04-04 | — | — | US | disclosed |
| EP-0232101-A2 | Light-sensitive silver halide color photographic material | KONICA CORPORATION (JP) | 1987-08-12 | — | — | EP | disclosed |
| US-4587210-A | COLORFASTNESS; DISCOLORATION INHIBITION; MAGENTA COUPLERS; WHITE BACKGROUND | FUJI PHOTO FILM CO., LTD. (JP) | 1986-05-06 | — | — | US | disclosed |
| US-3960571-A | 1-PHENYL-2-PYRAZOL-5-ONE MAGENTA COLOR FORMING COUPLER | Fuji Photo Film Co., Ltd. (JA) | 1976-06-01 | — | — | US | disclosed |
| US-3960571-A | 1-PHENYL-2-PYRAZOL-5-ONE MAGENTA COLOR FORMING COUPLER | Fuji Photo Film Co., Ltd. (JA) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | PARP1 3111/4885PARP10 2151/4885PARP15 2205/4885 |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | PARP1 1638/4885PARP10 2794/4885PARP15 1456/4885 |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | PARP1 1127/4885PARP10 1834/4885PARP15 876/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | PARP1 1507/4885PARP10 1730/4885PARP15 1609/4885 |
| US-20200239512-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | NEU1, NEU3, NEU2 | PARP1 459/4885PARP10 591/4885PARP15 468/4885 |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | PARP1 4625/4885PARP10 3256/4885PARP15 3553/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | PARP1 328/4885PARP10 896/4885PARP15 374/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | PARP1 1127/4885PARP10 1834/4885PARP15 876/4885 |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | PARP1 1987/4885PARP10 2228/4885PARP15 2124/4885 |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | PARP1 3111/4885PARP10 2151/4885PARP15 2205/4885 |
| US-20220031641-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION | CHRM3, CHAT, CHRM5 | PARP1 4334/4885PARP10 4528/4885PARP15 4455/4885 |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | PARP1 2549/4885PARP10 1443/4885PARP15 2183/4885 |
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | NEU1, NEU3, NEU2 | PARP1 459/4885PARP10 591/4885PARP15 468/4885 |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | PARP1 3600/4885PARP10 2810/4885PARP15 1852/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | PARP1 3600/4885PARP10 2810/4885PARP15 1852/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | PARP1 2549/4885PARP10 1443/4885PARP15 2183/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | PARP1 1127/4885PARP10 1834/4885PARP15 876/4885 |
| US-20020198135-A1 | Compositions for release of radiosensitizers, and methods of making and using the same | XRCC6, MRE11, RAD51 | PARP1 32/4885PARP10 492/4885PARP15 254/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | PARP1 2704/4885PARP10 3335/4885PARP15 3654/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | PARP1 758/4885PARP10 1770/4885PARP15 761/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | PARP1 1638/4885PARP10 2794/4885PARP15 1456/4885 |
| US-20240180891-A1 | SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES | PDXK, PLPBP, GLS | PARP1 811/4885PARP10 779/4885PARP15 1189/4885 |
| US-20070185171-A1 | Compounds and methods of use | VHL, PGF, PTGIS | PARP1 1341/4885PARP10 2682/4885PARP15 1291/4885 |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | EDNRA, PTGIS, EDNRB | PARP1 275/4885PARP10 567/4885PARP15 396/4885 |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | PARP1 3078/4885PARP10 2213/4885PARP15 2158/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | PARP1 328/4885PARP10 896/4885PARP15 374/4885 |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | ACACA, ACACB, ACAT1 | PARP1 862/4885PARP10 597/4885PARP15 540/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | PARP1 989/4885PARP10 1731/4885PARP15 992/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | PARP1 1684/4885PARP10 2946/4885PARP15 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.